Haemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis in a patient with leprosy.
Syed MufarrihHeather LusbyPatricia WatsonPublished in: BMJ case reports (2024)
Multidrug therapy has significantly reduced the global burden of Hansen's disease; however, complications from long-term treatment persist. A male resident of southern Kentucky, in his 30s and of Micronesian descent, presented with worsening abdominal pain associated with anorexia, fatigue, functional decline and occasional haemoptysis. He was compliant with multidrug therapy for leprosy. Laboratory investigations revealed pancytopenia. He was initially treated under a sepsis protocol and later switched to high-dose steroids due to a suspected immune reaction from missed corticosteroid doses. Despite aggressive treatment for refractory pancytopenia, the patient's condition deteriorated, and he passed away from cardiac arrest. Posthumous bone marrow biopsy revealed haemophagocytic lymphohistiocytosis secondary to disseminated histoplasmosis with bone marrow infiltration. This case highlights the importance of proactive fungal screening in immunocompromised leprosy patients, particularly in endemic regions, as early detection and timely intervention can prevent severe complications.
Keyphrases
- bone marrow
- cardiac arrest
- high dose
- randomized controlled trial
- end stage renal disease
- mesenchymal stem cells
- risk factors
- newly diagnosed
- abdominal pain
- case report
- chronic kidney disease
- intensive care unit
- single cell
- acute kidney injury
- pulmonary embolism
- cardiopulmonary resuscitation
- peritoneal dialysis
- patient safety
- combination therapy
- depressive symptoms
- quality improvement
- cell therapy
- ultrasound guided
- patient reported outcomes
- multidrug resistant
- drug induced
- smoking cessation